VRCA
Verrica Pharmaceuticals Inc
4.30$
-1.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -31.8% | +92.5% | +35.3% | -134.4% | – | +899.7% | +269.4% | +12.9% | -64.5% | -1.4% | +16.7% | – | |
| – | +14,084.1% | -94.5% | -52.4% | -19.7% | +43.7% | -32.3% | +16.8% | +124.5% | +26.3% | -36.5% | -1.2% | – | |
| – | -770.2% | – | +72.4% | -147.8% | – | – | +304.8% | +8.4% | -72.1% | +12.0% | +20.6% | – | |
| – | -18.3% | -7.0% | -32.9% | -27.5% | -51.5% | +95.7% | -19.2% | +19.4% | +14.3% | +53.2% | +56.3% | – | |
| – | -15.3% | -12.7% | +3.9% | -2.8% | -58.7% | +38.3% | +3.6% | +6.2% | -9.1% | +16.9% | +3.6% | – | |
| – | -82.9% | +367.1% | -6.8% | -6.8% | -39.8% | +0.2% | -4.0% | +8.5% | -8.4% | +30.2% | +30.6% | – | |
| – | – | – | – | – | – | – | – | +7.7% | -526.9% | – | – | – | |
| – | +39.1% | +0.6% | +2.1% | +0.3% | -1.1% | -6.2% | -3.3% | -1.7% | -37.2% | -87.8% | +2.5% | – | |
| – | – | – | – | – | – | – | – | -234.3% | – | – | – | – | |
| – | – | +30.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -234.3% | – | – | – | – | |
| – | – | – | – | – | – | – | – | -20.9% | -427.8% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.